Worth Buying,MART-1 Peptides

The MART-1 peptide, also known as Melan-A peptide, has emerged as a crucial molecule in the field of cancer research, particularly in the study and treatment of melanoma. This peptide is derived from the MART-1 protein, also identified as Melan-A, which is a melanoma antigen recognized by T cells. Its significance lies in its expression patterns and its role as a target for immune responses, making it a focal point for diagnostic markers and potential therapeutic strategies.

The MART-1 (Melan-A) gene is 18 kb long and comprises five exons. This protein is predominantly found in most skin cancers, including melanomas, and among normal cells, it is specifically expressed in melanocytes. This restricted expression pattern makes MART-1 a valuable biomarker for the diagnosis of melanoma. Furthermore, the MART-1 protein is a member of a melanocyte lineage-specific family of proteins. Its presence in melanoma, melanocyte cell lines, and the retina has been well-documented.

A specific region of the MART-1 protein, the MART-1 peptide (26-35), with the amino acid sequence EAAGIGILTV, has garnered significant attention. This particular sequence, corresponding to MART-1 amino acids 26-35, is a well-studied human tumor-associated antigen. It is recognized by cytotoxic T lymphocytes (CTLs) and is frequently involved in T-cell responses against malignant melanoma. The MART-1:27-35 HLA-A2-restricted peptide is a synthetic version that has been engineered with amino acid substitutions, such as leucine to alanine at position 27, to enhance its immunogenicity. In fact, the peptide MART1/melan A27-35 has been studied for its ability to elicit anti-melanoma CD8+ T cells with enhanced functional characteristics.

The immunogenicity of the MART-1 peptide has led to its extensive use in research and the development of immunotherapies. Various MART-1 peptides have been synthesized and utilized in T-cell assays, including ELISPOT, intracellular cytokine staining (ICS), and proliferation assays, to stimulate antigen-specific T cells. For instance, PepTivator Melan-A/MART-1 is a peptide pool designed to cover the complete sequence of the MART-1 protein, facilitating comprehensive immune response studies.

Clinical trials have explored the use of MART-1 peptide vaccines. In one such Phase I trial, patients were immunized with increasing doses of the MART-1(27-35) peptide to evaluate toxicity, tolerability, and immune responses. These vaccines, often made from a MART-1 peptide or antigen, are designed to help the body build an effective immune response to kill tumor cells. In some approaches, the MART-1 peptide was used with several other peptides to pulse autologous dendritic cells, which were then adoptively transferred.

Researchers have also focused on developing new generation of Melan-A/MART-1 peptides that offer enhanced immunogenicity and resistance to proteolysis. Analogs such as [Leu28, β-HIle30]MART-1(27-35) have demonstrated higher affinity to HLA-A2 and prolonged complex stability compared to their counterparts. These advancements aim to improve the efficacy of T-cell mediated therapies. The MART-1 (27-35) peptide has also been investigated in combination with other agents, like TLR4 agonists, to bolster the immune response.

The study of MART-1 and its associated peptides extends to understanding the underlying biology. For example, MART-1 is involved in melanosome biogenesis by ensuring the stability of GPR143. The complexity of the immune response to MART-1 is also an area of active research, with studies examining MART-1-specific CD8 T cells and their development from the thymus to the tumor.

The identification of immunodominant peptides from MART-1 has been a significant undertaking, with early research involving the synthesis of 23 peptides from MART-1 to pinpoint epitopes recognized by tumor-infiltrating lymphocytes (TIL). The ELAGIGILTV mutant peptide is one example that has been used to generate HLA-A*0201-restricted Melan-A/MART-1-specific CD8+ T cell clones.

In summary, the MART-1 peptide is a critical component in the understanding and potential treatment of melanoma. Its role as a tumor antigen, its expression in melanoma cells, and its ability to elicit immune responses have made it a vital subject of research. From diagnostic applications to the development of advanced immunotherapies, the MART-1 peptide continues to be a central figure in the fight against melanoma. The ongoing exploration of different peptides and their interactions with the immune system, including those that cover a broad range of different MHC alleles, promises further breakthroughs in this